Date Title Description PDF
27 Feb 2024 On P&L The Company releases the press release related to the full year 2023 financial results. Download
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download

Pages

15 / 46
Date Title Description PDF
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

100 / 158
Date Title Description PDF
09 Oct 2015 Otros sobre operaciones corporativas Download
08 Oct 2015 Otros sobre operaciones corporativas Download
30 Jul 2015 Información sobre resultados (2) Download
30 Jul 2015 Información sobre resultados Download
30 Jun 2015 Información sobre dividendos Download

Pages

125 / 194